BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 20 March 2008. doi:10.1136/bjo.2007.134429
British Journal of Ophthalmology 2008;92:655-660
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
bjo.2007.134429v1
92/5/655    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lipski, A
Right arrow Articles by Jurklies, B
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipski, A
Right arrow Articles by Jurklies, B
Topic Collections
Right arrow Editor's choice
Right arrowRelated Article

CLINICAL SCIENCE

Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations

A Lipski, N Bornfeld, B Jurklies

Department of Ophthalmology, University Hospital Essen, Essen, Germany

Correspondence to:
Dr A Lipski, Department of Ophthalmology, Universitätsklinikum Essen, Hufelandstraße 55, D-45122 Essen, Germany; andreas.lipski{at}uni-duisburg-essen.de

Background: Vision impairment in children and young adults may derive from choroidal neovascularisation (CNV) related to numerous conditions. The aim of this study is to highlight the applicability of photodynamic therapy using verteporfin (PDT) in these patients.

Methods: In 16 eyes of 16 consecutive patients aged 30 years or younger, prospective open-label PDT was performed. Outcomes of visual acuity as well as changes in CNV lesion parameters were evaluated.

Results: The mean patient age at first PDT was 19.7 (SD 8.7) years (range 6–30). 81% of the patients retained stable vision within two lines or exceedingly improved vision during follow-up of 34 (24) months. Significant vision gain was denoted in seven paediatric patients (2.7 (1.4) lines, mean (SD); p = 0.019) as well as in a subgroup of 12 patients not affected by active uveitis (2.6 (2.0) lines, p = 0.0005). Two patients with multifocal choroiditis and panuveitis (MCP) experienced vision losses of five and 11 lines after four PDT sessions despite receiving additional steroidal treatment. Except for one patient with MCP and two patients who dismissed follow-up, a mean of 2.2 (1.3) PDTs per patient sufficiently inactivated CNV lesions during follow-up. In the area of the former PDT spot, alterations of the pigment epithelium increased by 40% without correlation to changes in vision.

Conclusions: The results indicate good PDT efficacy and tolerability most promising in a subgroup of patients with vision-impairing CNV not associated with active uveitis. PDT in young patients with CNV remains a valuable treatment with good risk–benefit profile over the long term.


Funding: University Eye Clinic, Essen.

Competing interests: None.

Ethics approval: The design of the study was reviewed by the authors and the institutional review board. All procedures were in full accordance with local ethics board requirements.


Related Article

At a glance
Harminder S Dua and Arun D Singh
Br. J. Ophthalmol. 2008 92: 585. [Extract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.